CA-170
- Generic Name
- CA-170
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- -
- CAS Number
- -
- Unique Ingredient Identifier
- -
- Background
CA-170 is a selective, small molecule inhibitor of PD-L1.
- Associated Conditions
- -
- Associated Therapies
- -
Curis (CRIS) Stock Surges Over 6% Amid Biotechnology Sector Gain
Curis Inc. stock rose 6.53% to $5.38, with revenue of $2.55M and a net loss of $11.80M, EPS -$2.03. The biotech sector gained 0.32%, with Curis among active stocks. The company focuses on immuno-oncology and precision oncology drugs.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath